Literature DB >> 9174404

RET in human development and oncogenesis.

P Edery1, C Eng, A Munnich, S Lyonnet.   

Abstract

Hirschsprung disease and the multiple endocrine neoplasia type 2 syndromes are hereditary disorders related to the abnormal migration, proliferation or survival of neural crest cells and their derivatives. Hirschsprung disease is a frequent disorder of the enteric nervous system, resulting in intestinal obstruction. The multiple endocrine neoplasia type 2 syndromes predispose to cancers of neural crest derivatives. Both diseases are associated with heterozygous mutations in the RET proto-oncogene. RET encodes a transmembrane receptor tyrosine kinase expressed in neural crest lineages and whose ligand, glial-cell-line-derived neurotrophic factor, has been very recently identified. In vitro expression studies demonstrate that while Hirschsprung disease mutations result in loss of function of the mutant RET tyrosine kinase, multiple endocrine neoplasia type 2 mutations lead to its constitutive activation. Thus, the two 'faces' of RET, gain of function and loss of function, each lead to a different syndrome, respectively: multiple endocrine neoplasia type 2, a cancer syndrome, or Hirschsprung disease, a developmental defect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174404     DOI: 10.1002/bies.950190506

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  12 in total

1.  Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.

Authors:  Shannon D Barker; Sherri Bale; Jessica Booker; Arlene Buller; Soma Das; Kenneth Friedman; Andrew K Godwin; Wayne W Grody; Edward Highsmith; Jeffery A Kant; Elaine Lyon; Rong Mao; Kristin G Monaghan; Deborah A Payne; Victoria M Pratt; Iris Schrijver; Antony E Shrimpton; Elaine Spector; Milhan Telatar; Lorraine Toji; Karen Weck; Barbara Zehnbauer; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-09-18       Impact factor: 5.568

Review 2.  Neonatal tumours.

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

3.  Deletions in HOXD13 segregate with an identical, novel foot malformation in two unrelated families.

Authors:  F Goodman; M L Giovannucci-Uzielli; C Hall; W Reardon; R Winter; P Scambler
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

4.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13).

Authors:  C Popovici; J Adélaïde; V Ollendorff; M Chaffanet; G Guasch; M Jacrot; D Leroux; D Birnbaum; M J Pébusque
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

Review 5.  Clinical genetics of multiple endocrine neoplasias, Carney complex and related syndromes.

Authors:  C A Stratakis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

6.  C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B.

Authors:  C L Smith-Hicks; K C Sizer; J F Powers; A S Tischler; F Costantini
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

7.  Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes.

Authors:  M Zhou; A G Engel; A Auerbach
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 8.  Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 9.  Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.

Authors:  Terry-Elinor Reid; Joseph M Fortunak; Anthony Wutoh; Xiang Simon Wang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

10.  GDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase.

Authors:  Anna Popsueva; Dmitry Poteryaev; Elena Arighi; Xiaojuan Meng; Alexandre Angers-Loustau; David Kaplan; Mart Saarma; Hannu Sariola
Journal:  J Cell Biol       Date:  2003-04-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.